645 related articles for article (PubMed ID: 17561501)
1. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
Selleslag D; Vogelaers D; Marbaix S
Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands.
Jansen JP; Meis JF; Blijlevens NM; van't Wout JW
Curr Med Res Opin; 2005 Oct; 21(10):1535-46. PubMed ID: 16238893
[TBL] [Abstract][Full Text] [Related]
5. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?
Garbino J; Schnetzler G; Roberts C
Swiss Med Wkly; 2006 Sep; 136(39-40):624-30. PubMed ID: 17086508
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
Stam WB; Aversa F; Kumar RN; Jansen JP
Value Health; 2008; 11(5):830-41. PubMed ID: 18494752
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoeconomic assessment of therapy for invasive aspergillosis.
Luong ML; Husain S; Rotstein C
Mycoses; 2013 May; 56(3):338-49. PubMed ID: 23311989
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
10. Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Barnes R; Earnshaw S; Herbrecht R; Morrissey O; Slavin M; Bow E; McDade C; Charbonneau C; Weinstein D; Kantecki M; Schlamm H; Maertens J
Clin Ther; 2015 Jun; 37(6):1317-1328.e2. PubMed ID: 25891805
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
Mycoses; 2012 May; 55(3):244-56. PubMed ID: 21790799
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
Clemons KV; Espiritu M; Parmar R; Stevens DA
Antimicrob Agents Chemother; 2005 Dec; 49(12):4867-75. PubMed ID: 16304147
[TBL] [Abstract][Full Text] [Related]
13. Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis.
Greene RE; Mauskopf J; Roberts CS; Zyczynski T; Schlamm HT
Am J Health Syst Pharm; 2007 Dec; 64(24):2561-8. PubMed ID: 18056944
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.
Cesaro S; Toffolutti T; Messina C; Calore E; Alaggio R; Cusinato R; Pillon M; Zanesco L
Eur J Haematol; 2004 Jul; 73(1):50-5. PubMed ID: 15182338
[TBL] [Abstract][Full Text] [Related]
15. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
16. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
Bruynesteyn K; Gant V; McKenzie C; Pagliuca T; Poynton C; Kumar RN; Jansen JP
Eur J Haematol; 2007 Jun; 78(6):532-9. PubMed ID: 17419744
[TBL] [Abstract][Full Text] [Related]
17. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain.
Ostermann H; Solano C; Jarque I; Garcia-Vidal C; Gao X; Barrueta JA; De Salas-Cansado M; Stephens J; Xue M; Weber B; Charbonneau C
BMC Pharmacol Toxicol; 2014 Sep; 15():52. PubMed ID: 25253630
[TBL] [Abstract][Full Text] [Related]
18. Caspofungin versus liposomal amphotericin B for empirical therapy.
Danaher PJ
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
[No Abstract] [Full Text] [Related]
19. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.
Singh N; Limaye AP; Forrest G; Safdar N; Muñoz P; Pursell K; Houston S; Rosso F; Montoya JG; Patton P; Del Busto R; Aguado JM; Fisher RA; Klintmalm GB; Miller R; Wagener MM; Lewis RE; Kontoyiannis DP; Husain S
Transplantation; 2006 Feb; 81(3):320-6. PubMed ID: 16477215
[TBL] [Abstract][Full Text] [Related]
20. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]